Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Hematology  |  Oncology

Search Medical Condition
Please enter condition
Please choose location
Clear Trial Filters
 

Follicular Lymphoma Clinical Trials

A listing of Follicular Lymphoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (60) clinical trials

The purpose of this study is to evaluate the safety and tolerability of INCB050465 when combined with bendamustine and obinutuzumab in relapsed or refractory follicular lymphoma (FL).

Phase

Kappa-CD28 T Lymphocytes Chronic Lymphocytic Leukemia B-cell Lymphoma or Multiple Myeloma CHARKALL

To prepare the lymphoma, MM or CLL specific T cells investigators will take 240 ml (up to 16 tablespoonfuls)of blood from the patient. This would be drawn as 2 (two) separate blood collections of 120 ml (up to 8 tablespoonfuls) of blood. To get the kappa antibody (with CD28) to ...

Phase

Pilot Study for Patients With Chemotherapy Resistant or Refractory CD19 Leukemia and Lymphoma

This is an open label, single center, pilot study to evaluate the safety and tolerability, and differential persistence and engraftment of autologous T cells engineered to express a chimeric antigen receptor targeting CD19 which is linked either to the CD3 or CD3:4-1BB signaling chains in a competitive repopulation setting in ...

Phase

Collection of Tissue Samples for Cancer Research

Background: -Patients who are being evaluated and/or treated at the NIH Clinical Center or participating sites will be entered onto this tissue procurement protocol for collection of tissue specimens. Objectives: - To obtain samples for research purposes from tests performed for clinical & research indications on other research protocols. - ...

Phase

A Phase 1 Multiple Ascending Dose Study of DS-3032b an Oral Murine Double Minute 2 (MDM2) Inhibitor in Subjects With Advanced Solid Tumors or Lymphomas

This will be a Phase 1, open-label study of DS-3032b to assess its safety and tolerability, identify a maximum tolerated dose (MTD)/tentative recommended phase 2 dose (RP2D), and assess its pharmacokinetic (PK)/ pharmacodynamic (PD) properties in subjects with advanced solid tumors or lymphomas. Approximately 5 US sites are planned for ...

Phase

Phase I Dose-finding and Preliminary Efficacy Study of the Istodax in Combination With Doxil for the Treatment of Adults With Relapsed or Refractory Cutaneous T-cell Lymphoma

This a multi-center, single arm, open-label, Phase I dose-finding and preliminary efficacy study of the combination of the histone deacetylase inhibitor romidepsin (Istodax®) in combination with doxorubicin HCl liposomal (Doxil®) for adult patients with relapsed or refractory cutaneous T-cell lymphoma after at least one prior line of systemic therapy. STUDY ...

Phase

A Phase 1 Study Evaluating CPI-0610 in Patients With Progressive Lymphoma

First in human, open-label, sequential dose escalation and expansion study of CPI-0610 in patients with progressive lymphoma. CPI-0610 is a small molecule inhibitor of bromodomain and extra-terminal (BET) proteins.

Phase

Topical Romidepsin in Treating Patients With Stage I or Stage II Cutaneous T-Cell Non-Hodgkin's Lymphoma

OBJECTIVES: Primary - Determine the maximum tolerated dose of topical romidepsin when escalated by concentration, frequency, and body surface area in patients with stage IA, IB, or IIA cutaneous T-cell non-Hodgkin's lymphoma. - To monitor the skin and systemic toxicity of this drug in these patients. Secondary - Determine histone ...

Phase

Safety Study of CAT-8015 Immunoxin in Patients With NHL With Advance Disease

RATIONALE: The CAT-8015 immunotoxin can bind tumor cells and kill them without harming normal cells. This may be effective treatment for Non-Hodgkin's lymphoma (NHL) that has not responded to chemotherapy, surgery or radiation therapy. PURPOSE: Phase 1 dose escalation study to determine the maximum tolerated dose of CAT-8015 immunotoxin in ...

Phase

Ipilimumab in Young Patients With Advanced or Refractory Solid Tumors

OBJECTIVES: Primary - To determine the tolerance and toxicity profile of ipilimumab at a range of doses up to, but not exceeding, the highest dose tolerated in patients 21 years of age or younger with advanced or refractory solid tumors. - To assess the pharmacokinetics of ipilimumab in patients with ...

Phase